Axoltis announces SEALS results at Sachs BEF
Luca Bolliger will be on site for partnering discussions regarding NX210c. Axoltis shares topline Phase 2 trial data for ALS treatment.
See the latest news and media coverage for Axoltis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing neurological disease treatments
axoltis.comLast updated
In short: Axoltis reported NX210c’s ALS trial signals, although the Phase 2 study missed its primary endpoint.
Luca Bolliger will be on site for partnering discussions regarding NX210c. Axoltis shares topline Phase 2 trial data for ALS treatment.
Chief Business Officer Luca Bolliger will be on site at Messe Basel from October 6-8, 2026. The company shares recent SEALS Phase 2 trial topline results.
Topline data shows reduced functional decline and target engagement, supporting continued clinical development.
The SEALS trial showed NX210c has a good safety profile and suggests efficacy signals in ALS patients at week 6.
French biotech Axoltis reports a Phase 2 failure for NX210c in amyotrophic lateral sclerosis, missing the primary endpoint but showing secondary signals of slower disease progression.
Axoltis Pharma, a biotechnology company specialized in the development of innovative treatments against neurodegenerative diseases, announces the closing of a new funding round of...
Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9...
The phase II study of NX210c, the code name of Axoltis' candidate drug, should validate a repair of the blood-brain barrier. (DR) By Stephane Frachet...
Track Axoltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Axoltis and other trending companies.